

The Medical Letter[®]

on Drugs and Therapeutics

Volume 65

Published online January 24, 2023

Online
Article

IN THIS ISSUE

A New Indication for Dabrafenib (*Tafinlar*) and Trametinib (*Mekinist*) Combination Therapy

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 65

Published online January 24, 2023

Online
Article

IN THIS ISSUE

A New Indication for Dabrafenib (*Tafinlar*) and Trametinib (*Mekinist*) Combination Therapy

IN BRIEF

A New Indication for Dabrafenib (*Tafinlar*) and Trametinib (*Mekinist*) Combination Therapy

The oral kinase inhibitors dabrafenib (*Tafinlar* – GSK) and trametinib (*Mekinist* – Novartis) have received accelerated approval by the FDA for use together for a fifth indication: treatment of unresectable or metastatic solid tumors with a BRAF V600E mutation in patients ≥ 6 years old who have progressed following prior treatment and have no satisfactory alternative treatment options. The combination is not approved for treatment of colorectal cancer because of known intrinsic resistance to BRAF inhibition and dabrafenib is not approved for use in patients with wild-type BRAF melanoma, anaplastic thyroid cancer (ATC), or solid tumors.

MECHANISM OF ACTION – BRAF V600E mutations activate the mitogen-activated protein kinase (MAPK) pathway, including BRAF and mitogen-activated extracellular signal regulated kinase 1 (MEK1) and kinase 2 (MEK2), leading to cellular proliferation. Dabrafenib inhibits BRAF V600E and some other mutated forms of BRAF kinases. Trametinib inhibits MEK1 and MEK2 activity. The combination of dabrafenib and trametinib inhibits BRAF V600 mutation-positive tumor cells more than either drug alone.

CLINICAL STUDIES – Accelerated approval of the combination for the new indication was based on overall response and duration of response rates in open-label, multiple cohort trials in 131 adults and 36 children and previous studies in patients with melanoma and lung cancer. The new trials enrolled adults with BRAF V600E mutation-positive solid tumors, including low-grade glioma (LGG), high-grade glioma (HGG), biliary tract cancer, small intestine cancer, gastrointestinal stromal tumor,

Table 1. FDA-Approved Indications for Dabrafenib and Trametinib Combination Therapy

- ▶ Unresectable or metastatic melanoma with BRAF V600E or V600K mutations
- ▶ Adjuvant treatment of melanoma with BRAF V600E or V600K mutations and involvement of lymph nodes following complete resection
- ▶ Metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutations
- ▶ Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutations and no satisfactory locoregional treatment options
- ▶ Unresectable or metastatic solid tumors with BRAF V600E mutations in patients ≥ 6 years old who progressed following prior treatment and have no satisfactory alternative treatment options

and anaplastic thyroid cancer. One trial enrolled 36 children with BRAF V600 refractory or recurrent LGG or HGG. The primary endpoint in all of the trials was overall response rate (ORR). A total of 54 (41%) of 131 adults in the trials had an objective response. Among the highest representative tumor types in the clinical trials, ORR was 46% for biliary tract cancer, 33% for HGG, and 50% for LGG. The ORR was 25% in children.¹⁻⁷

ADVERSE EFFECTS – Common adverse effects of dabrafenib/trametinib in the clinical trials included pyrexia, fatigue, gastrointestinal adverse effects, rash, chills, headache, hemorrhage, cough, myalgia, arthralgia, and edema. In children, dry skin, dermatitis acneiform, abdominal pain, and paronychia also occurred.

DRUG INTERACTIONS – **Dabrafenib** is an inducer of UDP-glucuronosyltransferases and multiple CYP isoenzymes, including CYP3A4, 2B6, 2C8, 2C9, and 2C19.⁸ It may lower serum concentrations of midazolam, warfarin, dexamethasone, hormonal contraceptives, and many other drugs. Dabrafenib is primarily metabolized by CYP3A4 and 2C8; inhibitors or inducers of these enzymes may alter dabrafenib serum concentrations, resulting in loss of efficacy

or toxicity.⁹ Drugs that increase gastric pH, such as proton pump inhibitors, H₂-receptor antagonists, or antacids, may reduce the bioavailability of dabrafenib. **Trametinib** does not affect CYP isoenzymes and has no clinically significant drug interactions.

PREGNANCY AND LACTATION – The combination of dabrafenib/trametinib can cause fetal harm. Both drugs were embryotoxic and teratogenic in animal studies. Females of reproductive potential should be screened for pregnancy before starting dabrafenib/trametinib; they should use an effective nonhormonal contraceptive method while taking the combination and for 4 months after the last dose. Male patients with female partners of reproductive potential should use condoms during treatment with the combination and for at least 4 months after the last dose.

No data are available on the effects of the combination on the breastfed infant or milk production. Women should not breastfeed during treatment with these drugs.

DOSAGE, ADMINISTRATION, AND COST – Dabrafenib is available in 50- and 75-mg capsules and trametinib is available in 0.5- and 2-mg tablets. The recommended dosage for all indications in adults is dabrafenib 150 mg orally twice daily in combination with trametinib 2 mg orally once daily; both drugs should be taken 1 hour before or 2 hours after a meal. The recommended dosage of both drugs in children is based on body weight. Children who weigh 26-37 kg should receive 75 mg of dabrafenib twice daily and 1 mg of trametinib once daily and those who weigh 38-50 kg should receive 100 mg of dabrafenib twice daily and 1.5 mg of trametinib once daily. A recommended dose of either drug has not been established in patients who weigh <26 kg. The labels

of both drugs include dosage adjustments that should be made if adverse effects occur. A 30-day supply of *Tafinlar* and *Mekinist* for an adult costs about \$25,518.¹⁰

CONCLUSION – In clinical trials in patients ≥6 years old with unresectable or metastatic solid tumors with a BRAF V600E mutation, about 40% of adults and 25% of children who received the oral kinase inhibitors dabrafenib (*Tafinlar*) and trametinib (*Mekinist*) achieved a response. ■

1. V Subbiah et al. Dabrafenib plus trametinib in patients with BRAF^{V600E}-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. *Lancet Oncol* 2020; 21:1234.
2. V Subbiah et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600E-mutated anaplastic thyroid cancer. *J Clin Oncol* 2018; 36:7.
3. PY Wen et al. Dabrafenib plus trametinib in patients with BRAF^{V600E}-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. *Lancet Oncol* 2022; 23:53.
4. KT Flaherty et al. Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). *J Clin Oncol* 2020; 38:3883.
5. YK Chae et al. Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: results from the NCI-MATCH trial (EAY131) subprotocol w. *J Clin Oncol* 2020; 38:2407.
6. JA Whitlock et al. Dabrafenib, alone or in combination with trametinib, in pediatric patients with BRAF V600 mutation-positive Langerhans cell histiocytosis. *Blood* 2021; 138(Suppl 1):3618.
7. Dabrafenib (Tafinlar) and trametinib (Mekinist) for metastatic melanoma. *Med Lett Drugs Ther* 2013; 55:62.
8. H Yin et al. Inhibition of human UDP-glucuronosyltransferase enzyme by dabrafenib: implications for drug-drug interactions. *Biomed Chromatogr* 2021; 35:e5205.
9. Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. *Med Lett Drugs Ther* 2021 October 20 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
10. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. January 5, 2023. Reprinted with permission by First Databank, Inc. All rights reserved. ©2023. www.fdbhealth.com/policies/drug-pricing-policy.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org

Subscriptions (US):

1 year - \$159; 2 years - \$298;
3 years - \$398. \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints - \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.